The Food and Drug Administration on Wednesday issued an early alert about a “potentially high-risk” device issue involving power cords used with Outset Medical’s Tablo hemodialysis systems.
The agency said it is aware that Outset sent a letter on Nov. 10 to affected customers recommending that all Tablo systems have updated use instructions before continued use. The alert involves power cords used with the Tablo Console and the TabloCart with Prefiltration Drawer, specifically the power cord with clear ends (PN-0005746) and the power cord with gray ends (PN-0008460).
According to the FDA, Outset has received reports that the junction of the power cord and the power inlet on the Tablo Console and on the TabloCart with Prefiltration Drawer overheated. The company identified that events occur when the connector is not held firmly in the inlet, which can allow movement, increase electrical resistance, and generate heat at the connection. Reports have involved both the original clear-ended cord and the current gray-ended cord.
The FDA listed signs of overheating at the connection, including a burning or hot-plastic odor; smoke; the cord or connector feeling warm or hot; melting, charring or discoloration at the connector or inlet; sparks or flames; popping, crackling, sizzling or other electrical sounds; a loose or improperly seated connector; visible cracking, fraying or wear along the cord; a tripped circuit breaker; unexpected loss of power; or a console alarm related to power loss. The FDA said that if the connection overheats, someone who touches the hot connector could suffer a first- or second-degree burn, and the Tablo Console could lose power, leading to a delayed, interrupted, or missed treatment.
Outset’s Nov. 10 letter recommended users continue to operate Tablo Consoles and TabloCarts while taking specific steps. Before each use, staff should inspect the power cord and connection for warmth, a loose or improperly seated connector, cracking or fraying, or melting, charring or discoloration at the connector or power inlet. If any sign is present, the unit should not be used and Outset Technical Support should be contacted, the letter said. The company also advised ensuring the cord is fully inserted into the console (and TabloCart if present) and wall outlet; avoiding pulling, bending or straining at the connector; keeping the cord out of walkways; using only the Outset-supplied power cord; and not using extension cords or power strips. Users should stop use if signs of overheating appear, stop treatment per facility procedure, unplug the cord once it is safe to do so, then reach Outset Technical Support before putting the unit back into service. The notice should be shared with all staff and any organizations that have received a transferred unit, and home programs should inform patients, the letter said.
As of Nov. 10, 2026, Outset has reported no serious injuries or deaths tied to this issue, according to the FDA. The FDA said the Tablo Hemodialysis System is cleared for use in acute and chronic renal failure patients, with or without ultrafiltration, in acute or chronic care facilities.
The FDA said it is reviewing information about the issue and will update its web page as significant new information becomes available. The agency linked a related entry in its Medical Device Recall Database. U.S. customers with adverse reactions, quality problems or questions should contact Outset Medical at 844-698-2256 or support@outsetmedical.com, and may report problems to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.